My laboratory is focused on understanding how the immune system functions and on applying this knowledge to the development of immune-based therapies to treat cancer. We seek to bridge basic science and clinical medicine in order to develop novel strategies to treat cancer, including improving immune checkpoint therapy and adoptive cell therapy. We have ongoing collaborations with both industry and academic partners, and we are interested in new relationships that bring synergy and real-world solutions.
As part of our effort, we are studying lymphocyte biology and associated tumor immune inhibitory pathways. We are also studying how cytokines (such as IL-2 and IL-15) modulate immune responses, as well as developing novel protein- and antibody-based therapeutics.
My laboratory is also studying T-cell and antibody responses relevant to SARS-CoV2 vaccination or infection, including the impact of cancer therapies on the induction of long-lasting immunity. Finally, we are studying how pre-existing immunity with common coronaviruses impacts immunity to SARS-CoV2.